Meeting
2023 ASCO Annual Meeting
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
Authors
Jianxiang Wang
Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
Jianxiang Wang , Junyuan Qi , Wenyu Li , Zhimin Zhai , Ping Li , Wen Zou , Muran Ding , Xue Yang , Rong Wang , Wanjing Guo , Sa Xiao , Jahan S. Khalili , Hai Zhu , Martin Sebastian Olivo , Yi Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04606433
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2668)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2668
Abstract #
TPS2668
Poster Bd #
507b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher
Poster
2022 ASCO Annual Meeting
CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL).
First Author: Frederick L. Locke
Poster
2022 ASCO Annual Meeting
Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.
First Author: Jun Ma
Poster
2018 ASCO Annual Meeting
Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
First Author: Michelle A. Fanale